Company: CWAN
Filing Date: 2025-03-20
Form Type: 424B3
Source: 0001193125-25-058975
Chunk: 258

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-20
Form: 424B3
Chunk 258
---
CL WILL GOVERN.

182

LEGAL MATTERS

The legality of the shares of Clearwater Common Stock issuable in the Transactions will be passed upon for Clearwater by Kirkland &
Ellis LLP.

183

EXPERTS

Clearwater

The consolidated financial
statements of Clearwater Analytics Holdings, Inc. as of December 31, 2024 and 2023, and for each of the years in the three-year period ended December 31, 2024, and management’s assessment of the effectiveness of internal control over
financial reporting as of December 31, 2024, have been incorporated by reference herein in reliance upon the reports of KPMG LLP, independent registered public accounting firm, incorporated by reference herein, and upon the authority of said
firm as experts in accounting and auditing.

Enfusion

The consolidated financial statements of Enfusion, Inc. appearing in Enfusion, Inc.’s Annual Report (Form
10-K) for the year ended December 31, 2024, have been audited by Ernst & Young LLP, independent registered public accounting firm, as set forth in their report thereon, included therein, and
incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report given on the authority of such firm as experts in accounting and auditing.

184

ENFUSION STOCKHOLDER PROPOSALS

If the Merger Agreement is adopted and the Transactions are completed, Enfusion will become a wholly owned subsidiary of Clearwater or be
merged into Acquirer, and, consequently, there will be no annual meeting of Enfusion Stockholders in 2025 or thereafter. If the Merger Agreement is not adopted or the Transactions are not completed for any reason, Enfusion will hold an annual
meeting of its stockholders in 2025.

To be eligible for inclusion in Enfusion’s proxy statement for the 2025 annual meeting of
stockholders, stockholder proposals must have been received at Enfusion’s principal executive offices no later than December 27, 2024. Any stockholder who wishes to bring a proposal or nominate a person for election to the Enfusion Board
at the 2025 annual meeting must provide written notice of the proposal or nomination to the attention of Enfusion’s Legal Department no earlier than the close of business on February 13, 2025 nor later than the close of business on
March 15, 2025. In addition to satisfying the foregoing requirements under the Enfusion Bylaws, to